May 3rd 2024
Findings from a real-world study identified that venetoclax was a safe treatment option and did not lead to higher rates of death for patients with chronic lymphocytic leukemia who were diagnosed with COVID-19.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Frontline Obinutuzumab (Gazyva) Approved for CLL
November 1st 2013Obinutuzumab (Gazyva) plus chlorambucil has been approved by the FDA as a first-line treatment for patients with CLL, based on clinical trial data demonstrating that the combination more than doubled median PFS over the chemotherapy agent alone.
Read More
Ponatinib Trial Discontinued Following Occurrence of Arterial Thrombotic Events
October 21st 2013A phase III EPIC trial exploring ponatinib (Iclusig) in untreated patients with chronic myeloid leukemia (CML) has been discontinued. The decision comes following a high occurrence of arterial thrombotic events, according to a statement released by Ariad Pharmaceuticals, Inc., the company developing the drug.
Read More
Ofatumumab Receives Breakthrough Therapy Designation for Earlier Use in CLL
October 16th 2013The monoclonal antibody ofatumumab (Arzerra) has received Breakthrough Therapy designation from the FDA that could allow for earlier use in patients with chronic lymphocytic leukemia (CLL), according to a joint announcement released by GlaxoSmithKline and Genmab, who are developing and distributing the drug.
Read More
FDA Grants Breakthrough Therapy Designation for Volasertib
September 18th 2013The FDA has granted a Breakthrough Therapy designation to the novel PLK1 inhibitor volasertib in combination with LDAC for its potential as a treatment for patients with untreated AML who are ineligible for intensive remission induction therapy.
Read More
Potential Therapeutic Target Identified in Acute Myeloid Leukemia
May 17th 2013Researchers have determined that high expression of microRNA-155 was associated with a poorer prognosis in patients with AML and that inhibition of a molecule that regulates the microRNA may serve as a therapeutic target for these patients.
Read More